Business Context and Reporting Period
Company: OXIS International, Inc. (Note: Request metadata listed "GT Biopharma," but the filing text identifies the registrant as OXIS International, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2010
Business Overview: OXIS is a smaller reporting company focused on developing nutraceutical and therapeutic products based on oxidative stress reduction technologies, specifically L-Ergothioneine (ERGO). The company sold its historical diagnostic assay business in 2008 and has been restructuring to launch new products. As of the reporting date, the company had not yet commercially released its new products.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | Balance Sheet (Sep 30, 2010) |
|---|---|---|---|
| Total Revenue | $0 | $0 | N/A |
| Net Loss | $(633,000) | $(2,333,000) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $181,000 |
| Total Current Liabilities | N/A | N/A | $5,190,000 |
| Accumulated Deficit | N/A | N/A | $(79,433,000) |
| Working Capital Deficit | N/A | N/A | $(3,850,000) |
| Shares Outstanding | N/A | N/A | 144,277,804 |
Cash Flow (Nine Months Ended Sep 30, 2010): Net cash used in operating activities was $(1,158,000). Net cash provided by financing activities was $46,000 (primarily from option/warrant exercises).
Material Changes vs. Prior Period
- Revenue: The company reported $0 revenue for the three and nine months ended September 30, 2010, compared to $35,000 in the same periods of 2009. This reflects the complete cessation of the legacy assay business and the pre-revenue status of the new nutraceutical strategy.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased significantly to $1,811,000 for the nine months of 2010, up from $453,000 in 2009. This increase is attributed to new executive hires, increased overhead, and $507,000 in stock-based compensation for services.
- Research & Development: R&D expenses rose to $160,000 for the nine months of 2010 from $0 in the prior year, driven by development of ERGO-based products.
- Debt Conversions: During the nine months ended September 30, 2010, the company issued approximately 70.1 million shares of common stock to retire debt valued at $2,177,000.
Outlook, Risks, and Management Commentary
- Going Concern: Management explicitly states that the company's lack of revenue, current liabilities exceeding $5 million, and cash usage raise substantial doubt about its ability to continue as a going concern without additional financing.
- Liquidity: With only $181,000 in cash, the company anticipates it will not be able to sustain operations through the remainder of 2010 without raising additional capital.
- Recent Financing (Subsequent Event): On November 8, 2010, the company secured a $250,000 equity investment and a $750,000 line of credit from Gemini Pharmaceuticals, Inc., to fund product purchases. This included the issuance of Series I Preferred Stock and warrants.
- Product Launch: The company anticipates commercially releasing its first ERGO-based products later in 2010, with revenue generation expected to commence in the near future (potentially 2011).
- Defaults: The company is in default on its Secured Convertible Debentures issued in 2006 due to missed monthly redemption payments. While a Standstill and Forbearance Agreement is in place with the primary holder (Bristol Investment Fund, Ltd.), the holders retain the right to accelerate repayment and sell company assets.
Investor Verification Checklist
- Capital Adequacy: Verify the sufficiency of the $250,000 Gemini investment and $750,000 credit line against the $3.85 million working capital deficit.
- Debt Default Status: Confirm the current status of the 2006 Secured Convertible Debentures and whether the Standstill Agreement remains effective or if foreclosure risks have materialized.
- Product Timeline: Validate the projected timeline for the commercial release of ERGO-based products and the associated revenue forecasts.
- Dilution Risk: Assess the impact of outstanding warrants (76.7 million) and options (14.5 million) on existing shareholders, noting the significant share count increase from debt conversions in 2010.
- Going Concern Audit: Review the auditor's report (if available) or management's detailed plan for securing the additional equity or debt financing required to avoid insolvency.